Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Market Cap	32.34B
Revenue (ttm)	42.59M
Net Income (ttm)	-433.41M
Shares Out	168.46M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,179
Average Volume	338,040
Open	198.00
Previous Close	194.00
Day's Range	191.50 - 198.00
52-Week Range	122.00 - 329.50
Beta	0.11
RSI	42.24
Earnings Date	Nov 10, 2025

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 43
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2024, Lumosa Therapeutics's revenue was 39.15 million, a decrease of -31.21% compared to the previous year's 56.92 million. Losses were -424.78 million, 78.4% more than in 2023.